Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings

Amedisys (AMED) reported $621.86 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 5.2%. EPS of $1.54 for the same period compares to $1.32 a year ago.The reported revenue represents a surprise of +2% over the Zacks Consensus Estimate of $609.65 million. With the consensus EPS estimate being $1.39, the EPS surprise was +10.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amedisys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Service Revenue- High Acuity Care: $10.7 million versus $10.38 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.Net Service Revenue- Hospice: $215 million versus the three-analyst average estimate of $210.75 million. The reported number represents a year-over-year change of +5.4%.Net Service Revenue- Home health: $396.2 million versus the three-analyst average estimate of $386.85 million. The reported number represents a year-over-year change of +5%.View all Key Company Metrics for Amedisys here>>>Shares of Amedisys have returned -1.5% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks